Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture

Table 1 Baseline patient characteristics

Characteristic		Second-line, n = 22		Salvage therapy, n = 19		P value
Age, yr
	Median (range)	61.5	(29-73)	63	(42-81)	0.161
Sex
	Male	12	(55)	14	(74)	0.332
	Female	10	(45)	5	(26)
Tumor localization
	Left	14	(64)	13	(68)	1.002
	Right	8	(36)	6	(32)
Primary lesion resection
	Yes	12	(55)	15	(79)	0.192
	No	10	(45)	4	(21)
RAS status
	Wild	4	(18)	10	(53)	0.0262
	Mutant	18	(82)	9	(47)
RAF status
	Wild	1	(5)	0	(0)	1.002
	Unknown	21	(95)	19	(100)
Metastasis
	Liver	15	(68)	12	(63)	0.752
	Lung	7	(32)	8	(42)	0.532
	Others	14	(64)	11	(58)	0.702
Duration of prior AI administration
	< 6 mo	12	(55)	3	(16)	0.022
	≥ 6 mo	10	(45)	16	(84)
	Median, d (range)	144	(0-574)	323	(14-1119)	0.0061

Unless otherwise indicated, data are presented as n (%).

¹Student’s t-test.

²Fisher’s exact test.

AI: Angiogenesis inhibitor.